Imaging Features Predict Long-Term Survival in HCC Patients with Portal Vein Tumor Thrombus

What Is the Study’s Rationale and Design?

Recent clinical findings reveal promising imaging characteristics in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) who achieved long-term survival following combination therapy. A retrospective study from Chang Gung Memorial Hospital has identified specific radiological features and clinical indicators associated with extended survival in this typically poor-prognosis patient population. The research, which evaluated 26 patients with advanced HCC and PVTT who survived beyond one year after receiving combined tyrosine kinase inhibitors (TKIs) and radiotherapy, offers valuable insights into potential predictive markers for treatment response in this challenging clinical scenario. PVTT, occurring in 10-40% of HCC patients at diagnosis, typically confers a dismal prognosis of just 2-5 months with supportive care alone, making these findings particularly significant for clinical research teams and oncologists specializing in liver malignancies.

The study methodology involved selecting patients from a pool of 3,884 HCC cases treated between January 2010 and July 2021. Most participants (92.3%) had well-preserved liver function (Child-Pugh A) at baseline, with 53.8% classified as ALBI grade I. The treatment protocol consisted of systemic therapy with TKIs (sorafenib or lenvatinib) initiated upon PVTT confirmation, followed by radiotherapy approximately one month later. Radiotherapy was delivered using volumetric modulated arc therapy (VMAT) with doses ranging from 3000-5000 cGy over 10-20 fractions. Treatment response was assessed through computed tomography (CT) and magnetic resonance imaging (MRI) six months post-radiotherapy using RECIST 1.1 criteria. Two board-certified radiologists specialized in oncologic liver imaging independently analyzed all images, evaluating portal vein recanalization, collateral circulation development, and changes in liver volume. Laboratory parameters including alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, prothrombin time, and platelet counts were also monitored to assess liver function and treatment response comprehensively.

What Do Imaging and Biomarker Findings Indicate for HCC?

The demographic profile revealed a male predominance (69.2%) among the cohort, with hepatitis C virus infection being the most common etiology (13 patients), followed by hepatitis B (7 patients) and dual infection (4 patients). Liver cirrhosis was nearly universal among participants (96.2%), with other common comorbidities including alcohol use (42.3%), hypertension (34.6%), and diabetes mellitus (15.4%). These baseline characteristics reflect the typical profile of HCC patients in regions where viral hepatitis remains a significant risk factor. Following combination therapy, several noteworthy imaging features emerged among these long-term survivors. Portal vein recanalization occurred in 46.2% of patients, with four experiencing complete recanalization and eight showing partial restoration of blood flow. This finding suggests that restoration of portal venous circulation may serve as a positive prognostic indicator. Additionally, collateral circulation was observed either before or after radiotherapy in approximately half of the patients, potentially providing alternative routes for nutrient and oxygen supply to hepatocytes when the main portal vein remained occluded. Perhaps most intriguing was the compensatory hypertrophy of the contralateral liver segment noted in six patients with intraparenchymal portal vein occlusion, indicating the liver's remarkable capacity for adaptation even in advanced disease states.

Laboratory parameters also showed significant improvements following combination therapy. Serum AFP levels, a well-established tumor marker for HCC, declined in 16 patients, with more pronounced improvements observed in those with baseline levels below 100 ng/mL (p=0.022). Liver function, as assessed by ALBI grade, improved or remained stable in 65.4% of patients, while prothrombin time showed statistically significant improvement (p=0.008). Interestingly, platelet counts decreased significantly from 96.5 to 63 × 10³/μL (p<0.001) after treatment, a finding that aligns with previous research suggesting that thrombocytopenia may be associated with prolonged recurrence-free and overall survival following hepatectomy. The overall tumor response was encouraging, with 88.5% of patients achieving either stable disease or partial response according to RECIST 1.1 criteria. These combined radiological and laboratory findings suggest that the dual approach of TKIs plus radiotherapy may offer meaningful clinical benefits for selected HCC patients with PVTT, a group traditionally considered to have limited treatment options.

Could These Observations Transform HCC Management Despite Limitations?

The study's findings reinforce emerging evidence supporting combination therapy for HCC with vascular invasion. Previous research by Im et al. demonstrated improved median overall survival for HCC patients with major portal vein invasion when treated with radiotherapy plus other modalities compared to radiotherapy alone (10.4 vs. 8.7 months, p=0.023). The current study extends these observations by identifying specific imaging markers that may help predict favorable outcomes. The recanalization of tumor thrombus, development of collateral circulation, and compensatory liver hypertrophy appear to be radiological features associated with extended survival in this high-risk population. These imaging characteristics could potentially guide treatment decisions and help identify patients most likely to benefit from aggressive combination approaches. Additionally, the preservation of baseline liver function emerged as a critical factor for long-term survival, underscoring the importance of careful patient selection and liver-sparing treatment strategies even in advanced disease stages. The observation that smaller thrombus size (≤3 cm) may predict better local response aligns with previous research and suggests another potential imaging marker for effective PVTT control.

Despite these promising findings, several limitations warrant consideration when interpreting the results. The retrospective, single-center design and relatively small sample size limit the generalizability of the observations. The study focused exclusively on long-term survivors, introducing an inherent selection bias that precludes direct comparisons with patients who experienced shorter survival. Without a control group of short-term survivors, the findings must be viewed as descriptive characteristics rather than definitive prognostic factors. Additionally, the extended enrollment period spanning more than a decade introduces potential heterogeneity in patient management, particularly given the rapid advancements in systemic therapies for HCC during this timeframe. The authors acknowledge these limitations and appropriately call for larger, multicenter prospective studies to validate their observations. Future research should include comparative cohorts to better establish the prognostic value of the identified imaging features and explore whether these markers could guide treatment selection in clinical practice. Could the integration of these imaging characteristics into formal risk stratification models improve treatment decision-making for HCC patients with PVTT?

How Can Adverse Effects and Novel Therapies Inform Future Care?

The management of adverse effects remains an important consideration in combination therapy approaches. While the current study reported manageable toxicity profiles, with most patients completing radiotherapy without radiation-induced liver disease, the potential for increased adverse events with multimodality treatment deserves careful attention. Previous studies have suggested that combination therapies, while improving survival rates, may carry higher risks of adverse events that require proactive management strategies. The balance between efficacy and toxicity becomes particularly crucial in patients with compromised liver function or extensive disease. How might future protocols optimize the sequencing and dosing of combined TKI and radiotherapy to maximize efficacy while minimizing toxicity? Additionally, with the rapid evolution of systemic therapies for HCC, including immune checkpoint inhibitors and novel targeted agents, the optimal combination approach continues to evolve. Could newer systemic agents combined with radiotherapy yield even better outcomes than the TKI-based combinations evaluated in this study? These questions highlight the dynamic nature of HCC management and underscore the need for ongoing research in this challenging clinical scenario.

In conclusion, this retrospective analysis provides valuable insights into the imaging characteristics associated with long-term survival in HCC patients with PVTT following combination therapy with TKIs and radiotherapy. The recanalization of tumor thrombus, formation of collateral circulation, compensatory liver hypertrophy, and preservation of baseline liver function emerged as favorable features in this high-risk subgroup. While these findings require validation in larger, prospective studies, they suggest potential imaging markers that could guide treatment decisions and help identify patients most likely to benefit from aggressive combination approaches. As the therapeutic landscape for advanced HCC continues to evolve, these observations contribute to our understanding of the complex interplay between tumor biology, treatment response, and patient outcomes in HCC with vascular invasion. Could these imaging features eventually serve as early surrogate markers for treatment efficacy, allowing for more personalized and adaptive treatment strategies in this heterogeneous patient population? The answer awaits further investigation, but the current findings represent an important step toward improving outcomes for patients with this challenging manifestation of HCC.

Summary

A retrospective study from Chang Gung Memorial Hospital analyzed imaging characteristics and clinical outcomes in 26 hepatocellular carcinoma patients with portal vein tumor thrombus who survived beyond one year after receiving combined tyrosine kinase inhibitors and radiotherapy. The research identified several promising radiological features associated with extended survival in this typically poor-prognosis population, including portal vein recanalization (occurring in 46.2% of patients), development of collateral circulation, and compensatory hypertrophy of contralateral liver segments. Laboratory parameters also showed significant improvements, with serum alpha-fetoprotein levels declining in 16 patients and liver function remaining stable or improving in 65.4% of cases. Overall tumor response was encouraging, with 88.5% of patients achieving either stable disease or partial response according to standard criteria. The study suggests that specific imaging markers—including tumor thrombus recanalization, collateral circulation formation, and compensatory liver growth—may help predict favorable outcomes and guide treatment decisions for hepatocellular carcinoma patients with vascular invasion. Despite limitations including retrospective design, small sample size, and inherent selection bias from focusing exclusively on long-term survivors, these findings contribute valuable insights into potential predictive markers for treatment response in this challenging clinical scenario and highlight the need for larger prospective validation studies.